 |
|
|
LIRAGLUTIDE: A NEW OPTION FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS
This supplement is being made available for free download through an unrestricted educational grant from Novo Nordisk.
|
|
 |
Introduction Scott R. Drab, Pharm.D. |
|
Differentiating Incretin Therapies Based on Structure, Activity, and Metabolism: Focus on Liraglutide Samuel Grossman, Pharm.D. |
|
Pharmacokinetics and Pharmacodynamics of Liraglutide, a Long-Acting, Potent Glucagon-Like Peptide-1 Analog Jerry Meece, B.S., FACA |
|
Clinical Studies of Liraglutide, a Novel, Once-Daily Human Glucagon-Like Peptide-1 Analog for Improved Management of Type 2 Diabetes Mellitus Scott R. Drab, Pharm.D. |
|
The Intersection of Safety and Adherence: New Incretin-Based Therapies in Patients with Type 2 Diabetes Mellitus Barbara J. Zarowitz, Pharm.D., and Christopher Conner, Pharm.D., Ph.D. |
